Xin Lang Cai Jing·2025-11-12 01:37Group 1 - The core viewpoint of the news is that Guangdong Wannianqing Pharmaceutical Co., Ltd. has shown significant trading activity and financial performance indicators, with a notable increase in financing buy-ins and a decrease in shareholder numbers [1][2]. Group 2 - On November 11, Guangdong Wannianqing's stock rose by 2.53%, with a trading volume of 104 million yuan. The financing buy-in amount for the day was 13.32 million yuan, while the financing repayment was 7.94 million yuan, resulting in a net financing buy-in of 5.37 million yuan [1]. - As of November 11, the total financing and securities lending balance for Guangdong Wannianqing was 64.80 million yuan, which accounts for 2.22% of its market capitalization. This financing balance is above the 70th percentile level over the past year, indicating a relatively high position [1]. - The company has not engaged in securities lending activities on November 11, with no shares sold or repaid, and the securities lending balance remains at zero, placing it in the 90th percentile level over the past year [1]. Group 3 - As of September 30, the number of shareholders for Guangdong Wannianqing was 11,400, a decrease of 7.18% from the previous period. The average circulating shares per person increased by 7.74% to 13,994 shares [2]. - For the period from January to September 2025, Guangdong Wannianqing reported operating revenue of 22.8 million yuan, a slight decrease of 0.14% year-on-year. The net profit attributable to the parent company was -8.13 million yuan, representing a significant decline of 157.65% year-on-year [2]. - Since its A-share listing, Guangdong Wannianqing has distributed a total of 65.60 million yuan in dividends, with 40 million yuan distributed over the past three years [2].